Toxic amyloid-beta oligomer (AβO)

Toxic amyloid-beta oligomers (AβOs) are soluble, misfolded aggregates of the amyloid-beta peptide that are widely considered the primary neurotoxic species in Alzheimer's disease [7, 8]. Unlike physiological Aβ monomers or the insoluble fibrils found in amyloid plaques, these oligomers disrupt synaptic plasticity, inhibit long-term potentiation, and trigger downstream neurodegenerative processes such as tau hyperphosphorylation and neuroinflammation [8, 16]. The prion-like nature of these oligomers refers to their ability to act as seeds, inducing the misfolding of healthy Aβ monomers and propagating pathology throughout the brain [6, 13]. Therapeutic strategies targeting these species often focus on disease-specific epitopes (DSEs)—unique conformational shapes exposed only on the surface of misfolded oligomers [1, 3]. By selectively binding to these DSEs, monoclonal antibodies like PMN310 aim to neutralize toxic AβOs while sparing non-pathogenic monomers and avoiding the inflammatory side effects, such as amyloid-related imaging abnormalities (ARIA), associated with clearing established amyloid plaques [2, 5]. These oligomers are known to interact with various neuronal receptors, including the cellular prion protein (PrPc), which mediates their synaptotoxic effects [12, 15]. Current drug development efforts, such as those by ProMIS Neurosciences and Acumen Pharmaceuticals, utilize computational modeling to identify and target these transient, pathogenic structures with high precision [3, 6].

Other names

Toxic amyloid-beta oligomerAβ oligomerSoluble amyloid-beta oligomerPathogenic amyloid-beta aggregateMisfolded amyloid-beta oligomerToxic prion-like amyloid-beta oligomers bearing disease-specific epitopes

Selective neutralization of toxic soluble amyloid-beta oligomers by binding to conformational disease-specific epitopes, thereby preventing their interaction with neuronal receptors and inhibiting neurotoxic signaling pathways.